TAK-653 Reverses Core Depressive Symptoms in Chronic Stress-Induced Monkey Model.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Major Depressive Disorder (MDD) is a significant global health concern requiring novel therapeutic strategies.
• Glutamate system dysfunction is implicated in the pathophysiology of depression.
• The efficacy of TAK-653, an AMPA receptor positive allosteric modulator, in primate models of depression remains uninvestigated.

Purpose of the Study:

• To evaluate the antidepressant-like effects of TAK-653 in a nonhuman primate model of depression.
• To investigate the impact of TAK-653 on stress-induced behavioral and physiological changes.

Main Methods:

• A 12-week chronic unpredictable mild stress (CUMS) protocol was used to induce depression-like phenotypes in monkeys.
• Monkeys were treated with TAK-653 for two weeks following the CUMS protocol.
• Behavioral assessments and plasma analyses (cortisol, IL-6, IL-8, BDNF) were conducted.

Main Results:

• CUMS induced depression-like behaviors (reduced motivation, increased huddling, decreased activity, anxiety) and elevated cortisol, IL-6, and IL-8 levels.
• TAK-653 treatment significantly reversed these behavioral deficits and normalized cortisol and IL-6 levels.
• TAK-653 treatment also increased Brain-Derived Neurotrophic Factor (BDNF) expression.

Conclusions:

• TAK-653 demonstrates significant antidepressant-like efficacy in a nonhuman primate model of depression.
• The findings support TAK-653 as a potential novel therapeutic agent for Major Depressive Disorder.
• Modulation of the AMPA receptor system offers a promising avenue for depression treatment.